<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250051</url>
  </required_header>
  <id_info>
    <org_study_id>NU 19H05</org_study_id>
    <secondary_id>STU00210558</secondary_id>
    <secondary_id>NU 19H05</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <secondary_id>NCI-2019-08390</secondary_id>
    <nct_id>NCT04250051</nct_id>
  </id_info>
  <brief_title>Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agios Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ivosidenib when given together&#xD;
      with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that&#xD;
      has come back (relapsed) or does not respond to treatment (refractory). Ivosidenib may stop&#xD;
      the growth of cancer cells by blocking the IDH1 mutation and some of the enzymes needed for&#xD;
      cell growth. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and&#xD;
      filgrastim, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib&#xD;
      with combination chemotherapy may work better in treating patients with acute myeloid&#xD;
      leukemia compared to chemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of ivosidenib in combination with&#xD;
      fludarabine, cytarabine, plus granulocyte-colony stimulating factor (G-CSF) (FLAG)&#xD;
      chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the safety profile of ivosidenib in combination with FLAG chemotherapy.&#xD;
&#xD;
      II. To determine the rate of complete remission (CR + complete remission with incomplete&#xD;
      hematological recovery [CRi] + complete remission with incomplete platelet recovery [CRp])&#xD;
      with ivosidenib in combination with FLAG chemotherapy.&#xD;
&#xD;
      III. To evaluate the 1 year progression free survival. IV. To evaluate the 1 year overall&#xD;
      survival. V. To assess the number of patients that receive allogeneic stem cell transplant&#xD;
      after ivosidenib in combination with FLAG chemotherapy.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess for minimal residual disease negativity by polymerase chain reaction (PCR) for&#xD;
      IDH1 mutations after treatment with ivosidenib in combination with FLAG chemotherapy.&#xD;
&#xD;
      II. To assess for minimal residual disease negativity by PCR for IDH1 mutations after 3&#xD;
      cycles of maintenance therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INDUCTION: Patients receive filgrastim subcutaneously (SC) once daily (QD) on days 0-6,&#xD;
      fludarabine phosphate intravenously (IV) QD over 30 minutes on days 1-5, cytarabine IV QD&#xD;
      over 4 hours on days 1-5, and ivosidenib orally (PO) QD on days 7-28. Treatment continues for&#xD;
      28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD&#xD;
      over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD&#xD;
      on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days&#xD;
      for up to 26 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every month&#xD;
      for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 28, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT)</measure>
    <time_frame>Up to day 42 of the first treatment cycle</time_frame>
    <description>Will be assessed for a DLT per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
    <description>Will be assessed by the CTCAE version 5.0. Toxicity profiles will be summarized for toxicities of any grade, with rates of &gt;= grade 3 toxicities also analyzed separately. Adverse events rates will be summarized and accompanied by 95% exact binomial confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of complete remission (CR + complete remission with incomplete hematological recovery [CRi] + complete remission with incomplete platelet recovery [CRp])</measure>
    <time_frame>After induction on day 28 or upon count recovery, up to 1 year</time_frame>
    <description>Patients that complete the induction cycle will be eligible for assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will be estimated using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year</time_frame>
    <description>Will be estimated using Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that receive hematopoietic stem cell transplant after induction treatment</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Patients that complete the induction cycle will be eligible for assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Myelodysplastic Syndrome</condition>
  <condition>Recurrent Myeloproliferative Neoplasm</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION: Patients receive filgrastim SC QD on days 0-6, fludarabine phosphate IV QD over 30 minutes on days 1-5, cytarabine IV QD over 4 hours on days 1-5, and ivosidenib PO QD on days 7-28. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
CONSOLIDATION: Patients receive filgrastim SC QD on days 0-5, fludarabine phosphate IV QD over 30 minutes on days 1-4, cytarabine IV QD over 4 hours on days 1-4, and ivosidenib PO QD on days 1-28. Treatment continues for 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE: Patients receive ivosidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivosidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (combination chemotherapy, ivosidenib)</arm_group_label>
    <other_name>AG-120</other_name>
    <other_name>Tibsovo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have relapsed/refractory primary (ie, de novo) or secondary (progression&#xD;
             of myelodysplastic syndrome [MDS] or myeloproliferative neoplasms [MPN], or&#xD;
             therapy-related) acute myeloid leukemia (AML) according to the World Health&#xD;
             Organization (WHO) classification with &gt;= 5% leukemic blasts in the bone marrow&#xD;
&#xD;
          -  Patients may have received prior therapies and there are no limits on number of&#xD;
             therapies&#xD;
&#xD;
               -  Note: There is a requirement of 7 day washout from prior therapy or 5 half-lives,&#xD;
                  whichever is shorter&#xD;
&#xD;
          -  Patient must have documentation of an IDH1 R132 mutation obtained prior to&#xD;
             registration. IDH mutational status will be assessed locally&#xD;
&#xD;
          -  Patients must understand and voluntarily sign an informed consent form (ICF) prior to&#xD;
             any study-related assessments/procedures being conducted&#xD;
&#xD;
          -  Patient is willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or&#xD;
             2&#xD;
&#xD;
          -  Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT)&#xD;
             and alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x&#xD;
             upper limit of normal (ULN), unless considered due to leukemic organ involvement&#xD;
             (within 28 days prior to registration)&#xD;
&#xD;
          -  Serum total bilirubin &lt; 1.5 x ULN (within 28 days prior to registration)&#xD;
&#xD;
               -  Higher levels are acceptable if these can be attributed to ineffective&#xD;
                  erythropoiesis, =&lt; 3 times the upper limit of normal for Gilbert's syndrome (eg,&#xD;
                  a gene mutation in UGT1A1), or leukemic organ involvement&#xD;
&#xD;
          -  Serum creatinine or creatinine clearance &lt; 2 x ULN or &gt;= 30 mL/min based on the&#xD;
             Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR) (within&#xD;
             28 days prior to registration)&#xD;
&#xD;
          -  Patients must agree to serial bone marrow aspirate/biopsies&#xD;
&#xD;
          -  Females of childbearing potential (FOCBP) may participate, providing they meet the&#xD;
             following conditions: Agree to practice true abstinence from sexual intercourse or to&#xD;
             use two highly effective contraceptive methods, of which one must be a barrier method&#xD;
             (eg, combined [containing estrogen and progestogen] or progestogen only associated&#xD;
             with inhibition of ovulation, oral, injectable, intravaginal, patch, or implantable&#xD;
             hormonal contraceptive; bilateral tubal occlusion; intra-uterine device; intrauterine&#xD;
             hormone-releasing system; or male partner sterilization [note that a vasectomized&#xD;
             partner is a highly effective birth control method provided that partner is the sole&#xD;
             sexual partner of the FOCBP trial participant and that a vasectomized partner has&#xD;
             received medical assessment of the surgical success]) at screening and throughout the&#xD;
             study, and for at least 4 months following the last study treatment.&#xD;
&#xD;
               -  NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a&#xD;
                  tubal ligation, or remaining celibate by choice) who meets the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Has not undergone a hysterectomy or bilateral oophorectomy&#xD;
&#xD;
                    -  Has had menses at any time in the preceding 12 consecutive months (and&#xD;
                       therefore has not been naturally postmenopausal for &gt; 12 months)&#xD;
&#xD;
          -  Female patients must have a negative serum beta-subunit of human chorionic&#xD;
             gonadotropin (beta-hCG) pregnancy test (sensitivity of at least 25 mIU/mL) 28 days&#xD;
             prior to registration on study and have a negative serum or urine (investigator's&#xD;
             discretion under local regulations) Î²-hCG pregnancy test (sensitivity of at least 25&#xD;
             mIU/mL) within 72 hours prior to the start of study treatment in the Treatment Period.&#xD;
&#xD;
               -  Note: the screening serum pregnancy test can be used as the test prior to the&#xD;
                  start of study treatment in the Treatment Period if it is performed within the&#xD;
                  72-hour time frame)&#xD;
&#xD;
          -  Male patients must agree to practice true abstinence from sexual intercourse or agree&#xD;
             to the use of highly effective contraceptive methods (as described above) with&#xD;
             non-pregnant female partners of child bearing potential at screening and throughout&#xD;
             the course of the study and should avoid conception with their partners during the&#xD;
             course of the study and for at least 4 months following the last study treatment.&#xD;
&#xD;
               -  Furthermore, the male subject must agree to use a condom while treated with&#xD;
                  ivosidenib and for at least 4 months following the last ivosidenib dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are suspected or proven to have acute promyelocytic leukemia based on&#xD;
             morphology, immunophenotype, molecular assay, or karyotype are not eligible&#xD;
&#xD;
          -  Patients who have had prior therapy with ivosidenib are not eligible.&#xD;
&#xD;
               -  Note: prior treatment with other IDH inhibitors are allowed&#xD;
&#xD;
          -  Patients who have immediate life-threatening, uncontrolled medical problem that would&#xD;
             prevent treatment on a clinical trial per investigator's discretion are not eligible&#xD;
&#xD;
          -  Patients who have significant active cardiac disease within 28 days prior to study&#xD;
             registration, including New York Heart Association (NYHA) class III or IV congestive&#xD;
             heart failure; acute coronary syndrome (ACS); and/or stroke; or left ventricular&#xD;
             ejection fraction (LVEF) &lt; 40% by echocardiogram (ECHO) or multi-gated acquisition&#xD;
             (MUGA) scan obtained within 28 days prior to study registration are not eligible&#xD;
&#xD;
          -  Patients who have prior history of malignancy, other than MDS, MPN, or AML are not&#xD;
             eligible unless the subject has been free of the disease for &gt;= 1 year prior to the&#xD;
             start of study treatment. However, subjects with the following history/concurrent&#xD;
             conditions are allowed:&#xD;
&#xD;
               -  Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Carcinoma in situ of the breast Incidental histologic finding of prostate cancer&#xD;
                  (T1a or T1b using the tumor, node, metastasis clinical staging system)&#xD;
&#xD;
          -  Patients who are known to have short-gut syndrome, gastroparesis, or other conditions&#xD;
             that limit the ingestion or gastrointestinal absorption of drugs administered orally&#xD;
             are not eligible&#xD;
&#xD;
          -  Patients who are taking the following sensitive CYP substrate medications that have a&#xD;
             narrow therapeutic range are excluded from the study unless the subject can be&#xD;
             transferred to other medications at least 5 half-lives or 14 days whichever is shorter&#xD;
             prior to the start of study treatment: phenytoin (CYP2C9), S-mephenytoin (CYP2C19),&#xD;
             thioridazine (CYP2D6), theophylline, tizanidine (CYP1A2), CYP2C8, CYP3A4/5, and CYP2B6&#xD;
&#xD;
          -  Patients who are known to be taking strong CYP3A4 inducers or sensitive CYP3A4&#xD;
             substrate medications that have a narrow therapeutic window are not eligible, unless&#xD;
             they can be transferred to other medications within &gt;= 5 half-lives prior to dosing or&#xD;
             unless the medications can be properly monitored during the study&#xD;
&#xD;
          -  Patients with an active uncontrolled systemic fungal, bacterial, or viral infection&#xD;
             (defined as ongoing signs/symptoms related to the infection without improvement&#xD;
             despite appropriate antibiotics, antiviral therapy, and/or other treatment) are not&#xD;
             eligible&#xD;
&#xD;
          -  Patients who have known or suspected hypersensitivity to any of the components of&#xD;
             study therapy are not eligible&#xD;
&#xD;
          -  Patient who has corrected QT (QTc) interval (Frederica's correction [QTcF]) &gt;= 480 ms)&#xD;
             at screening unless attributable to bundle branch block or pacemaker are not eligible.&#xD;
             If prolonged QTc is attributed to medications the patient must be transferred to other&#xD;
             medications and QTc corrected to selection parameters prior to enrollment&#xD;
&#xD;
          -  Female patients who are pregnant or nursing are not eligible&#xD;
&#xD;
          -  Patients who have any significant medical condition, laboratory abnormality, or&#xD;
             psychiatric illness that the treating physician believes would prevent the subject&#xD;
             from participating in the study are not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shira N Dinner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>(312)695-1301</phone>
    <email>cancertrials@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shira N. Dinner, M.D.</last_name>
      <phone>312-695-6180</phone>
      <email>Shira.dinner@nm.org</email>
    </contact>
    <investigator>
      <last_name>Shira N. Dinner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Ivosidenib</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

